Differences in efficacy between imported and domestically produced lenvatinib

The efficacy of lenvatinib may vary somewhat between countries, depending on the manufacturer and the drug's quality control standards. Whether it is imported or domestically produced lenvatinib, its main pharmacological effects and efficacy should be similar. However, individual responses may vary for certain diseases or specific patient groups. Doctors often consider a patient's specific condition and the availability of medications to determine the best treatment option.

Imported lenvatinib is usually manufactured by the original developer, Eisai Co., Ltd., and is approved to treat differentiated thyroid cancer, advanced renal cell carcinoma, inoperable hepatocellular (liver) cancer, and endometrial cancer. These companies usually have extensive R&D experience and advanced production technology. They strictly follow international quality standards to ensure the quality and safety of medicines. Domestic lenvatinib may be produced by different pharmaceutical companies. Common manufacturers include Chia Tai Tianqing, Qilu Pharmaceutical, etc., and the quality control standards may be different. Pharmaceutical companies in some countries have obtained approval from strict drug regulatory agencies, and the quality and efficacy of their products are comparable to imported drugs.

LenvatinibThe original drug has been launched in China and is covered by Class B medical insurance. The price of each box may be more than 3,000 yuan. The original drug Lenvatinib currently on the market overseas may cost more than RMB 1,000 per box (the price may fluctuate due to exchange rates). Lenvatinib generic drugs are also produced and marketed overseas. Their drug ingredients are basically the same as those of the original drugs sold domestically and abroad, but the price is cheaper. For example, the price of each box produced by a Bangladeshi pharmaceutical factory may be 800 yuan (the price may fluctuate due to exchange rates).